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Abstract
Background: Current recommendations for empirical antimicrobial therapy in spontaneous bacterial peritonitis
(SBP) are based on quite old trials. Since microbial epidemiology and the management of patients have changed,
whether these recommendations are still appropriate must be confirmed.
Methods: An observational study that exhaustively collected the clinical and biological data associated with
positive ascitic fluid cultures was conducted in four French university hospitals in 2010–2011.
Results: Two hundred and sixty-eight documented positive cultures were observed in 190 cirrhotic patients
(median age 61.5 years, 58.5% Child score C). Of these, 57 were classified as confirmed SBP and 140 as confirmed
bacterascites. The predominant flora was Gram-positive cocci, whatever the situation (SBP, bacterascites,
nosocomial/health-care related or not). Enteroccocci (27.7% E. faecium) were isolated in 24% of the episodes, and in
48% from patients receiving quinolone prophylaxis. E. coli were susceptible to amoxicillin-clavulanate and to
third-generation cephalosporins in 62.5% and 89.5% of cases, respectively. No single antibiotic allowed antimicrobial
coverage of more than 60%. Only combinations such as amoxicillin + third-generation cephalosporin or
cotrimoxazole allowed coverage close to 75-80% in non-nosocomial episodes. Combinations based on broader
spectrum antibiotics should be considered for empirical therapy of nosocomial infections.
Conclusions: Our study confirmed the changing spectrum of pathogens in SBP and bacterascites, and the need for
more complex antibiotic strategies than those previously recommended. Our findings also underline the need for
new clinical trials conducted in the current epidemiological context.
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Background
Spontaneous bacterial peritonitis (SBP), defined as an in-
fection of ascites in the absence of a contiguous source
of infection, is a frequent and severe complication in cir-
rhotic patients, with a significant risk of mortality, ran-
ging initially from more than 80% in historical reports to
10-30% in the most recent studies [1-3]. Early diagnosis
and early optimal treatment of these infections with ap-
propriate antibiotics and the prevention of hepatorenal
syndrome with albumin are required [4]. Current European
and most other international guidelines recommend the
use of a third-generation cephalosporin as the first choice,
or amoxicillin-clavulanate acid or fluoroquinolones as an
alternative choice [5-7]. These recommendations are based
mainly on clinical trials that were very often conducted a
decade or more ago, and on the assumption that E. coli
would be involved in nearly half of the cases.
Several studies have pointed out changes in the epidemi-
ology of the causative bacteria in SBP and bacterascites and
in their susceptibility to antibiotics. In particular, the devel-
opment of beta-lactamase enzymes, which confer resistance
to clavulanate, or extended spectrum beta-lactamases in
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Escherichia coli [8]. The potential emergence of enterococci,
methicillin-resistant S. aureus, or fluoroquinolone-resistant
bacteria, following norfloxacin prophylaxis, is also a cause of
concern since they may be associated with a higher risk of
therapeutic failure [9].
There is thus a need for regular epidemiological studies.
We previously conducted a retrospective multi-center
study in North Eastern France, which showed the growing
implication of Gram positive bacteria, in particular
enterococci, and the increasing frequency of acquired
antimicrobial resistance among some of the bacteria
involved (in particular E Coli) [10].
A new 2-year observational study was conducted in
the same area to confirm the changes in the spectrum
of causative pathogens in SBP and bacterascites, their




The study was conducted in four university hospitals in
north-eastern France (Besançon, Dijon, Nancy and
Strasbourg) between 1st January 2010 and 31st December
2011, in compliance with the Helsinki Declaration and
the approval of IDD Ethics Committee. All the infectious
agents isolated from peritoneal liquid in cirrhotic pa-
tients hospitalized during this period were systematically
and prospectively recorded by the referent microbiolo-
gist of the participating hospital. There was no limitation
regarding the indication of paracentesis, but infectious
agents isolated from peritoneal dialysis or from secondary
bacterial peritonitis were not included. When the same
strain was isolated twice or more from the same patient
within a month, only the first was considered.
Microbiological and biological data
For each positive ascitic fluid culture, the biological charac-
teristics of the ascitic fluid, as well as the microbiological
characteristics of the infectious agent (s) isolated were re-
corded. Antibiotic susceptibility was assessed with antibiotic
disks (Bio-Rad, Marnes-la –Coquette, France; or Vitek 2
System, Bio Mérieux, Tassin la demi-lune, France) according
to the 2010–2011 updated recommendations of the CA-
SFM (comité de l’Antibogramme de la Société Française de
Microbiologie) (http://www.sfm-microbiologie.org). In the
determination of the antimicrobial coverage of antibiotics,
intermediate strains were considered resistant. Multi-drug
resistant bacteria were defined as vancomycin-resistant
enterococci, methicillin-resistant staphylococci, extended-
spectrum betalactamase-producing Gram-negative bac-
teria, carbapenemase-producing Gram-negative bacteria,
and Gram-negative bacteria resistant to multiple clas-
ses of antibiotics (i.e. at least three usually-active drugs from
different classes, in particular penicillins + beta-lactamase
inhibitors, antipseudomonal penicillins + beta-lactamase in-
hibitors, 2nd generation cephalosporins, 3rd generation ceph-
alosporins, cephamycins, monobactams, aminoglycosides,
folate pathway inhibitors, fosfomycin, fluoroquinolones).
SBP was defined as bacterial growth with an ascitic
neutrophil count above 250/mm3, whereas bacterascites
was defined as bacterial growth with an ascitic neutro-
phil count below this threshold [2,11]. When the ascitic
neutrophil count was not available (because of immediate
bedside inoculation into culture bottles and/or failure
to count neutrophils), the cases were not classified into
these two categories.
The infection was deemed nosocomial when the as-
citic fluid paracentesis was performed after 48 hours of
hospitalization. The infection was deemed related to health
care when it was nosocomial and/or when it occurred in pa-
tients with previous repeated and/or recent hospitalization
(<3 months) for medical care. Thus, though a nosocomial
infection is always health-care related, a health-care related
infection may be not nosocomial.
Clinical data collection
The clinical presentation at the time of ascitic fluid para-
centesis and the different antibiotics administered were col-
lected by the local investigator for each positive ascitic fluid
culture, in particular to ensure that no secondary peritonitis
was suspected. The final outcome (i.e. in hospital survival)
was also collected.
Statistical analyses
Categorical variables were compared using Fisher’s exact
and chi-square tests, and continuous variables using the
Kruskall Wallis test. Analyses were performed in the
whole group, in the subgroup with available ascitic
neutrophil counts (allowing differentiation between SBP
and bacterascites), and distinguishing between nosocomial
or not, or health-care related or not. Since it cannot be
excluded that coagulase-negative staphylococci were skin
contaminants, even when associated with an ascitic
neutrophil count above 250/mm3, sensitivity analyses
were repeated after excluding the episodes involving
coagulase-negative staphylococci. A backward step-by-
step logistic regression was conducted for multivariate
analysis of the factors associated with clinical outcome,
including all of the factors associated in univariate analysis
with a p value of less than 0.10.
All tests were two-sided and a p-value of less than
0.05 was considered statistically significant. All statistical
analyses were done using Stata version 12.0.
Results
Study population
During the two-year study period, 6,220 samples of
ascitic fluid from 1659 patients were analyzed. At
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least one infectious agent was found in 268 samples
(4.3%). Of the 190 patients with at least one positive
ascitic fluid culture, 80% were hospitalized in hepatol-
ogy wards.
The median age of these patients at their first infection
was 61.5 years (interquartile range (IQR): 53.4-69.8). There
were 137 men and 53 women, most of whom presented
severe cirrhosis (58.9% Child C, 36.3% Child B and 4.7%
Child A) with a median Child score of 10 (IQR 8–12). The
mean number of ascitic fluid samples in which an infec-
tious agent was isolated was 1.41 +/−0.92 per patient, and
the mean number of infectious agents isolated per positive
sample was 1.29 +/− 0.77. Ten percent of these patients
were on quinolone prophylaxis.
Characteristics of the positive ascitic fluid cultures
Biological and microbiological data
The characteristics and the distribution of infectious
agents involved in the 268 infections are shown in
Table 1. Overall, Gram-positive cocci were found to be
predominant (64.9%) followed by Gram-negative rods
(33.9%), and 84.3% of the infections were monomicro-
bial. In all the plurimicrobial cases (15.7%, mainly in-
volving only 2 infectious agents), secondary peritonitis
was clinically excluded. MDR bacteria were involved
in 34 episodes (13 vancomycin-resistant enterococci,
3 methicillin-resistant Staphylococcus aureus, 10 extended
betalactamases-producing E Coli, 17 other multiresistant
Gram-negative bacteria).
Fifty-seven (21.3%) positive ascitic fluid samples
were classified as confirmed SBP, 140 (52.2%) as con-
firmed bacterascites, and 71 (26.5%) could not be clas-
sified because of missing neutrophil counts (mainly
because of immediate bedside inoculation into culture
bottles without associated assessment of the neutro-
phil count). The SBP/bacterascites ratio was thus
close to 1/2.5.
The median neutrophil count in the ascitic fluid was
92/mm3 (range 0–9700), and the median protein con-
centration was 14 g/L (range 2–125). In patients with
confirmed SBP, the median neutrophil count in the
ascitic fluid was 880/mm3 (range 270–9700), and the
median protein concentration was 15 g/L (range 4–35).
The median neutrophil count was higher in ascitic fluids
with Gram-negative cocci than in those with Gram-positive
ones (100 vs. 77/mm3, p = 0.003).
No significant difference in microbial distribution was
observed between SBP and bacterascites, except for a
non-significant trend towards a greater proportion of
Gram negative rod infections in SBP (p = 0.09) even though
such infections were still in the minority (40.4% vs. 56.1%
Gram-positive cocci in SBP, respectively). MDR bacteria
were more often involved in SBP than in bacterascites
(19.3% vs. 7.1%, p = 0.006).
Nosocomial and/or health care related episodes
Ascitic liquid fluid paracentesis was performed within the
first 48 hours of hospitalization for 109 (40.7%) episodes,
thus defined as non-nosocomial. As 20 of these episodes
followed repeated or recent hospitalizations, the number of
potentially health-care related episodes was 179 (66.8%).
MDR bacteria were also significantly more often found in
nosocomial (17.6% vs. 5.5% in non-nosocomial episodes,
p = 0.002) and in healthcare-related episodes (16.2% vs.
5.6% in non-healthcare-related episodes, p = 0.006).
In all cases, Gram-positive cocci were predominant.
However, pneumococci and Staphylococcus aureus, albeit
rare, were more frequently isolated in non-nosocomial
episodes, as were Gram-negative anaerobes, whereas
enterococci were more frequently isolated in nosoco-
mial and healthcare-related episodes. Indeed, the same
distribution was observed in the 179 healthcare-related
positive ascitic fluid samples as in the 89 non-healthcare-
related samples, with a higher frequency of entero-
cocci (31.3% vs. 10.1%, p = 0.0001 and of Pseudomonas
aeruginosa (5.0% vs. 0.0%, p = 0.04), and a lower implication
of pneumococci (0.0% vs. 4.5%, p = 0.01).
Enterococci (E. faecium in 18/65, 27.7%) were also iso-
lated significantly more often in ascitic fluids from patients
with previous quinolone prophylaxis (48.1% vs. 21.6% in
those without quinolone prophylaxis, p = 0.04). The dif-
ference was even greater when considering SBP alone
(50.0% in those with vs. 15.6% in those without quinolone
prophylaxis, p = 0.02). KES (Klebsiella, Enterobacter and
Serratia spp.) were also found more frequently in patients
with previous quinolone prophylaxis (Table 1).
Coverage of antimicrobials for positive ascitic fluid cultures
The effective coverage of antimicrobials for all of the infec-
tious agents found in each positive ascitic fluid culture is
shown in Table 2.
Many antibiotics used alone offer antimicrobial coverage
close to 50%, but none allowed coverage higher than 60%.
Excluding coagulase-negative staphylococci increased the
expected coverage of most beta-lactams, except for third
generation cephalosporins. The expected coverage of other
antibiotics was unmodified, except that of glycopeptides,
which was nearly 12% lower.
The coverage was similar for confirmed SBP and bac-
terascites, except for glycopeptides and cotrimoxazole,
which showed lower coverage in SBP. Coverage for
amoxicillin and amoxicillin-calvulanate was nearly 10%
higher in non-nosocomial or non-healthcare–related
than in nosocomial or healthcare-related) infections,
respectively, and coverage for third-generation cephalo-
sporins was more than 25% higher in non-nosocomial and
non-healthcare-related infections.
The coverage of antimicrobials used alone or in com-
bination in non-nosocomial infections (after exclusion of
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Table 1 Distribution of the main infectious agents isolated in 268 ascitic fluid samples during the period 2010–2011






(n = 109) (n,%)
Nosocomial
episodes
(n = 159) (n,%)
p1 SBP (n = 57)
(n,%)
Bacterascites
(n = 140) (n,%)
p2 With FQ
prophylaxis
(n = 27) (n,%)
Without FQ
prophylaxis
(n = 241) (n,%)
p3
Streptococcus (other than S. pneumoniae) 33 (12.3%) 70 (21–150) 17 (15.6%) 16 (10.1%) 0.18 5 (8.8%) 18 (12.9%) 0.42 2 (7.4%) 31 (31.9%) 0.41
Streptococcus pneumoniae 4 (1.5%) 955 (200–1710) 4 (3.7%) 0 (0.0%) 0.01 1 (1.8%) 1 (0.7%) 0.51 0 (0.0%) 4 (1.7%) 0.50
Enterococcus sp. 65 (24 .3%) 75 (25–565) 15 (13.8%) 50 (31.4%) 0.0009 13 (22.8%) 31 (22.1%) 0.92 13 (48.1%) 52 (21.6%) 0.02
Staphylococcus aureus 7 (2.6%) 392 (18–815) 6 (5.5%) 1 (0.6%) 0.01 0 (0.0%) 0 (0.0%) - 1 (3.7%) 6 (2.5%) 0.71
Coagulase negative Staphylococcus 73 (27.2%) 63 (8–155,5) 25 (22.9%) 48 (30.2%) 0.19 13 (22.8%) 47 (33.6%) 0.14 4 (14.8%) 69 (28.6%) 0.13
Gram positive cocci 174 (64.9%) 77 (10–310) 67 (61.5%) 107 (67.3%) 0.33 32 (56.1%) 91 (65.0%) 0.24 20 (74.7%) 154 (63.9%) 0.29
Escherichia coli 48 (17.9%) 129 (86–830) 20 (18.3%) 28 (17.6%) 0.88 15 (26.3%) 21 (15.0%) 0.06 3 (11.1%) 45 (18.7%) 0.33
Klebsiella sp.Enterobacter sp. Serratia sp. 29 (10.8%) 92 (58–549) 10 (9.2%) 19 (11.9%) 0.47 5 (8.8%) 10 (7.1%) 0.70 6 (22.2%) 23 (9.5%) 0.04
Pseudomonas sp. 9 (3.4%) 59 (44–670) 0 (0.0%) 9 (5.7%) 0.01 0 (0.0%) 5 (3.6%) 0.15 0 (0.0%) 9 (3.7%) 0.31
Gram negative rods 91 (34.0%) 100 (66–660) 32 (29.4%) 59 (37.1%) 0.18 23 (40.4%) 39 (27.9%) 0.09 9 (33.3%) 82 (34.0%) 0.94
Anaerobes 11 (4.1%) 112 (12–500) 8 (7.3%) 3 (1.9%) 0.03 2 (3.5%) 4 (2.9%) 0.81 0 (0.0%) 11 (4.6%) 0.26
Fungi 7 (2.6%) 52 (30–55) 2 (1.8%) 5 (3.1%) 0.51 0 (0.0%) 3 (2.1%) 0.27 0 (0.0%) 7 (2.9%) 0.37
Not all the infectious agents are listed in this table. Since several agents were isolated in the same sample of ascitic fluid, the total may exceed 100%.
1comparison between non-nosocomial and nosocomial episodes.
2comparison between SBP and bacterascites.



















coagulase-negative staphylococci) or in confirmed SBP is
shown in Table 3.
Clinical outcome
Fifty-one patients (26.8%) died, 119 (62.6%) were dis-
charged and 20 (10.5%) were still in hospital at the end
of the study. Death was significantly associated with SBP
(37.0% vs. 18.5%, p = 0.01), but no statistically significant
association was found for the empirical antimicrobial
treatment given (whether active or not against the isolated
infectious agents). Other factors positively associated with
death in univariate analysis (p < 0.10) were age (p = 0.05),
ascitic neutrophil count (p = 0.04), involvement of E. coli
(p = 0.007) and MDR bacteria (p = 0.07), whereas there
was an inverse correlation between the involvement of
coagulase-negative staphylococci and death (p = 0.01). No
association was found between gender, the nosocomial
or healthcare-related nature of the infection, the ascitic
protein concentration, the use of fluoroquinolone prophy-
laxis, appropriate empirical therapy, or the total duration
of antibiotic therapy and death.
In multivariate analysis, age (Odds Ratio (OR) 1.03 per
year increment, Confidence Interval (95% CI): 1.00-1.06,
p = 0.02), Child stage (OR 3.15 per stage increment, 95%
CI: 1.57-6.32, p = 0.001) and MDR bacteria involvement
(OR 2.30, 95% CI: 0.98-5.38, p = 0.055) were or tended
to be significantly associated with death. These associ-
ations were similar when coagulase-negative staphylo-
cocci episodes were excluded.
Discussion
Our study shows that: the spectrum of causative agents of
SBP has changed since the EASL recommendations for the
management of SBP [5], and thus that recommendations
on antibiotics therapy should probably take into account
these changes in bacterial epidemiology.
While Gram negative rods were the main infectious
agents a few decades ago, and are still reported to be
so in the most recent recommendations and reviews
[6,12], our study confirmed that Gram positive cocci
are now predominant, even when skin contaminants
such as coagulase-negative staphylococci are excluded,
or when the analysis is restricted to confirmed SBP or
to non-nosocomial infections [10,13,14]. Moreover, even
though the global implication of E Coli is declining slightly,
the proportion of E Coli that produce betalactamase
(including extended-spectrum betalactamase) is increasing,
as is the proportion of E Coli with reduced susceptibility
to fluoroquinolones, as already reported [9]. In addition,
the proportion of enterococci infections is increasing, as
already reported by us and others [10,13,14]. Enterococci
were involved in nearly a quarter of the cases in our study,
and these infections appear to be significantly associated
with the use of quinolone prophylaxis, in particular in pa-
tients with confirmed SBP. Thus, quinolone prophylaxis,
which is widely accepted and used by physicians in primary
or secondary prevention of SBP [15], reduces the risk of in-
fection, but favors the emergence of bacteria with natural
or acquired resistance, such as enterococci, that are able
to translocate [6,16]. This has to be kept in mind when
considering fluoroquinolone prophylaxis, in particular for
primary prophylaxis of SBP, which should be restricted to
cirrhotic patients with low-protein ascites (<15 g/L), poor
liver function and a fragile hemodynamic status, and to
patients who are recovering from an episode of SBP who
have a high risk of developing SBP [5,6].
Secondly, and in keeping with this evolving epidemi-
ology, the currently recommended first-line antibiotic






staphylococci (n = 195)
Non-nosocomial
episodes (n = 109)
Nosocomial






Amoxicillin 33.2% 45.6% 40.4% 28.3% 0.04 40.4% 33.3% 0.37
Amoxicillin + clavulanate 42.5% 53.3% 50.5% 38.1% 0.02 43.9% 44.3% 0.96
Broad-spectrum penicillin 35.4% 48.7% 38.5% 33.3% 0.38 40.4% 39.3% 0.89
Broad-spectrum penicillin +
beta lactamase inhibitor
48.1% 64.1% 51.4% 45.9% 0.38 47.4% 50.7% 0.67
Third-generation cephalosporin 39.2% 39.0% 55.0% 28.3% <0.0001 33.3% 42.1% 0.25
Fluoroquinolone 46.6% 46.7% 57.8% 39.0% 0.002 38.6% 47.1% 0.27
Aminoglycoside 50.0% 47.2% 56.9% 45.3% 0.06 47.4% 52.9% 0.48
Cotrimoxazole 42.2% 38.4% 53.2% 34.6% 0.002 29.8% 45.7% 0.04
Glycopeptide 57.8% 45.6% 60.6% 56.0% 0.45 50.9% 66.5% 0.04
Percentages indicate the in vitro antimicrobial efficacy on the infectious agent (s) isolated in positive ascitic fluid cultures.
(intermediate strains were considered non-susceptible).
1comparison between non-nosocomial and nosocomial episodes.
2comparison between SBP and bacterascites.
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Table 3 In vitro susceptibility to antibiotics alone (first row or column) or in combination (other rows/columns) on the infectious agents isolated either from
non-nosocomial ascitic fluids after exclusion of coagulase negative staphylococci (upper right half) or from confirmed spontaneous bacterial peritonitis
(including coagulase negative staphylococci , lower left half)






Fluoro-quinolone Aminoglycosides Cotrimoxazole Glycopeptide
n = 57
- 47.6% 63.1% 65.5% 54.8% 57.1% 50.0% 47.6% 50.0%
Amoxicillin 40.4% - - 77.4% 78.6% 82.1% 77.4% 69.0%
Amoxicillin-clavulanate 43.9% - - - 81.0% 83.3% 81.0% 78.6%
Piperacillin-tazobactam 47.4% - - - 79.8% 79.8% 78.6% 85.7%
Third generation cephalosporin 33.3% 56.1% - - 72.6% 69.0% 69.0% 84.5%
Fluoroquinolone 38.6% 61.4% 61.4% 61.4% 49.1% - 65.5% 84.5%
Aminoglycosides 47.4% 73.7% 73.7% 68.4% 56.1% - 66.7% -
Cotrimoxazole 29.8% 57.9% 57.9% 57.9% 45.6% 49.1% 47.3% 78.6%
Glycopeptide 50.9% 71.9% 71.9% 80.7% 77.2% 84.2% - 73.3%
Combinations with in vitro coverage above 75% are in grey.
Most frequently found bacteria isolated from ascitic fluid samples (n = 268): coagulase negative staphylococci (n = 73): enterococci (n = 65), Escherichia coli (n = 48), streptococci (n = 32), and KES (Klebsiella, Enterobacter,
Serratia) bacteria (n = 29).
Most frequently found bacteria isolated from non-nosocomial ascitic fluid samples (n = 109): coagulase negative staphylococci (n = 24), Escherichia coli (n = 20), streptococci (n = 17), enterococci (n = 16), and KES
(Klebsiella, Enterobacter, Serratia) bacteria (n = 10).
Most frequently found bacteria isolated from confirmed SBP (n = 57): Escherichia coli (n = 15), coagulase negative staphylococci (n = 13), enterococci (n = 13), streptococci (n = 7), and KES (Klebsiella, Enterobacter,



















(third-generation cephalosporin alone) covered only
one third of the infectious agents isolated from SBP in
our study, and the two alternative choices (amoxicilline-
clavulanate and fluoroquinolones) did not sufficiently
increase the antimicrobial coverage. Even when only non-
nosocomial, or non-health-care related, or non-coagulase-
negative staphylococci infections were considered, no
single therapy was able to offer antimicrobial coverage
of more than 60%. This contrasts with the high clinical
efficacy observed in previous reports, and particularly
in clinical trials conducted between 1985 and 2000
[5,17,18]. The immediate use of antibiotic combinations for
the empirical treatment of ascitic fluid infections should be
considered, even though there is no strong clinical evidence
to support this suggestion, nor any assessment of the
impact on microbial resistance. The type of antibiotic
combination may differ depending on the situation, as
already suggested [19].
Amoxicillin clavulanate, cefotaxime, ceftriaxone, fluoro-
quinolones, teicoplanin and cotrimoxazole have satisfactory
pharmacokinetics at significantly higher concentrations than
the MICs of susceptible common pathogens in ascitic
fluid [20-24]. Thus, as we observed in non-nosocomial
episodes, combinations such as amoxicillin + third-gener-
ation cephalosporin, amoxicillin-clavulanate + cotrimoxazole
or to a lesser extent amoxicillin-clavulanate + fluroquinolone
(in patients without quinolone prophylaxis) may be of
particular interest, considering their coverage and their
limited risk of toxicity in cirrhotic patients. In nosocomial
episodes (and particularly in SBP), teicoplanin could be an
interesting association partner for betalactams (in particular
piperacillin-tazobactam or penems). New broad-spectrum
drugs such as ceftarolin should also be considered in
specific studies.
Whether these suggested combinations are associated
with a better clinical benefit than the currently recom-
mended therapy has to be established. In the present
study, although we observed a high in-hospital death
rate (37% in SBP and 18.5% in bacterascites), we failed
to demonstrate a survival benefit associated with the use
of early appropriate antimicrobial therapy, even though
we were unable to reliably adjust to the different associ-
ations used in current practice, the different timing and
durations, and moreover the different management of
comorbidities. The trend towards a higher risk of mor-
tality associated with the involvement of MDR bacteria
may not only be linked to greater therapeutic difficul-
ties, but also highlight a surrogate marker of repeated
exposure to antibiotics and of more frequent and longer
hospitalizations. In addition, the fact that ascitic neutro-
phil counts were not systematically assessed and that
antimicrobial therapy for confirmed SBP was not used
systematically may have affected the results of the study,
even though there was no clear difference between these
unclassified episodes and the others. In addition, bac-
terascites must be considered a serious condition given
the mortality rate we observed in patients with confirmed
bacterascites (close to 20%), even though it is probably
in part also a surrogate marker of advanced liver disease.
Another potential limitation is that the statistical power
may be insufficient, since the incidence of positive ascitic
fluid culture (and of SBP) was lower than that observed a
few years ago in the same area. Last, and more generally,
microbial epidemiology may also vary from one region to
another or from one ward to another [6].
Conclusion
Physicians have to be aware of the limits of antimicrobial
therapy. Recommended first-line treatments are at risk of
becoming ineffective on the infectious agents involved, at
least in culture-positive SBPs. However, they may still be
effective in patients with negative ascitic fluid cultures.
Quinolone prophylaxis, even though associated with a
clinical benefit by lowering the frequency of infectious
episodes, is also likely to increase the involvement of
bacteria with acquired or natural resistance to quino-
lones, such as enterococci. Combinations such as
amoxicillin + third-generation cephalosporin, or amoxicillin-
clavulanate + cotrimoxazole, deserve to be considered in
non-nosocomial episodes in patients with a severe clinical
presentation, and in those with no biological improvement
in the ascitic fluid after 48 hours of first-line therapy. Last,
since the benefits and the risks of such proposals have
to be established, there is a need not only for surveys
but also for new clinical trials that include the newest
broad-spectrum antibiotics conducted in the current
epidemiological context.
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